NA
PRQR icon

NewEdge Advisors’s ProQR Therapeutics PRQR Stock Holding History

NewEdge Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200
Closed -$324 – 3613
2023
Q2 		$324 Hold
200
– – ﹤0.01% 3353
2023
Q1 		$426 Hold
200
– – ﹤0.01% 3253
2022
Q4 		$1 Buy
+200
New +$262 ﹤0.01% 4031

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewEdge Advisors's PRQR Position: Q3 2023 in Review

NewEdge Advisors sold out of ProQR Therapeutics (PRQR) in Q3 2023, closing a stake of 200 shares — an estimated $324 sold.

NewEdge Advisors first reported a position in PRQR in Q4 2022 and held it in 3 quarters. The position peaked at $426 in Q1 2023. 46 funds tracked by Wall St. Rank hold PRQR as of Q3 2023.

  • NewEdge Advisors reported no remaining ProQR Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewEdge Advisors sold 200 ProQR Therapeutics shares in Q3 2023, an estimated $324.
  • NewEdge Advisors first reported a position in ProQR Therapeutics in Q4 2022 and held it in 3 quarters.
  • NewEdge Advisors's ProQR Therapeutics position peaked at $426 in Q1 2023.
  • 46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2023.

Based on NewEdge Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.